Breaking News

Myeloid Therapeutics Gets $73M Financing for mRNA-based Immunotherapy Pipeline

Proceeds will support the continued clinical development of MT-101, Myeloid's lead cell therapy program.

Myeloid Therapeutics, Inc., a clinical stage mRNA-immunotherapy company, completed a $73 million financing led by Hatteras Investment Partners, with participation from new investors ARCH Venture Partners and Moore Strategic Ventures. Existing investors, including Newpath Partners, 8VC and Alexandria Venture Investments, also participated. Proceeds from the financing will support the continued clinical development of MT-101, Myeloid’s lead cell therapy program in Phase 1/2 for T cell lym...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters